MXPA03000440A - Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma. - Google Patents

Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma.

Info

Publication number: MXPA03000440A
Authority: MX; Mexico
Prior art keywords: processes; preparation; drug substance; low hygroscopic; aripiprazole drug
Prior art date: 2001-09-25

Application number

MXPA03000440A

Other languages

English (en)

Inventor

Satoshi Aoki

Original Assignee

Otsuka Pharma Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-09-25

Filing date

2002-09-25

Publication date

2003-10-06

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27171631&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA03000440(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-03-27 Priority claimed from CA 2379005 external-priority patent/CA2379005A1/en

2002-09-25 Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd

2003-10-06 Publication of MXPA03000440A publication Critical patent/MXPA03000440A/es

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Addiction (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Hospice & Palliative Care (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Psychology (AREA)
Otolaryngology (AREA)
Gynecology & Obstetrics (AREA)
Anesthesiology (AREA)
Child & Adolescent Psychology (AREA)
Diabetes (AREA)
Obesity (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Quinoline Compounds (AREA)

MXPA03000440A 2001-09-25 2002-09-25 Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma. MXPA03000440A (es)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
JP2001290645		2001-09-25
JP2001348276		2001-11-14
CA 2379005 CA2379005A1 (en)	2001-09-25	2002-03-27	Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
PCT/JP2002/009858 WO2003026659A1 (en)	2001-09-25	2002-09-25	Low hygroscopic aripiprazole drug substance and processes for the preparation thereof

Publications (1)

Publication Number	Publication Date
MXPA03000440A true MXPA03000440A (es)	2003-10-06

Family

ID=27171631

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MXPA03000440A MXPA03000440A (es)	2001-09-25	2002-09-25	Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma.

Country Status (23)

Country	Link
US (20)	US20040058935A1 (es)
EP (6)	EP1927357B1 (es)
JP (3)	JP3760264B2 (es)
CN (16)	CN101574348B (es)
AR (2)	AR033485A1 (es)
AT (5)	ATE465737T1 (es)
AU (1)	AU2002334413C1 (es)
BR (1)	BR0205391A (es)
CA (6)	CA2688915C (es)
CY (1)	CY1118195T1 (es)
DE (5)	DE60235995D1 (es)
DK (5)	DK1927356T3 (es)
ES (5)	ES2343220T3 (es)
HU (1)	HUP0600141A3 (es)
IL (3)	IL153838A0 (es)
MX (1)	MXPA03000440A (es)
NO (7)	NO328134B1 (es)
PE (1)	PE20090124A1 (es)
PL (1)	PL225415B1 (es)
PT (5)	PT1927355E (es)
SI (4)	SI1330249T1 (es)
UA (1)	UA84764C2 (es)
WO (1)	WO2003026659A1 (es)

Families Citing this family (119)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR032641A1 (es) *	2001-01-29	2003-11-19	Otsuka Pharma Co Ltd	Agonista de subtipo de receptor 5-ht 1a.
US7053092B2 (en)	2001-01-29	2006-05-30	Otsuka Pharmaceutical Co., Ltd.	5-HT1a receptor subtype agonist
US8703772B2 (en)	2001-09-25	2014-04-22	Otsuka Pharmaceutical Co., Ltd.	Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
AR033485A1 (es)	2001-09-25	2003-12-26	Otsuka Pharma Co Ltd	Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
BR0313602A (pt)	2002-08-20	2005-06-21	Bristol Myers Squibb Co	Método e formulação de complexo de aripiprazol
AU2003291757A1 (en) *	2002-11-08	2004-06-03	Bristol-Myers Squibb Company	Formulations of low solubility bioactive agents and processes for making the same
AR042806A1 (es) *	2002-12-27	2005-07-06	Otsuka Pharma Co Ltd	Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
KR100858852B1 (ko)	2002-12-27	2008-09-17	오쓰까 세이야꾸 가부시키가이샤	기분 장애 치료용 카르보스티릴 유도체 및 세로토닌 재흡수억제제
SI1480953T2 (sl) †	2003-01-09	2010-12-31	Otsuka Pharma Co Ltd	Postopek za pripravo aripiprazola
EP1618103A2 (en) *	2003-04-25	2006-01-25	Cadila Healthcare Ltd.	Polymorphs of aripiprazole
EP2601953A1 (en)	2003-05-23	2013-06-12	Otsuka Pharmaceutical Co., Ltd.	Carbostyril derivatives and mood stabilizers for treating mood disorders
US7456181B2 (en)	2003-07-25	2008-11-25	Hetero Drugs Limited	Aripiprazole crystalline forms
UY28501A1 (es)	2003-09-10	2005-04-29	Astrazeneca Uk Ltd	Compuestos químicos
TWI371274B (en)	2003-10-23	2012-09-01	Bristol Myers Squibb Co	Process for making sterile aripiprazole of desired mean particle size
PL1675573T4 (pl)	2003-10-23	2016-04-29	Otsuka Pharma Co Ltd	Sterylny preparat do wstrzykiwań arypiprazolu o kontrolowanym uwalnianiu i sposób
US7714129B2 (en)	2003-12-16	2010-05-11	Teva Pharmaceutical Industries Ltd.	Methods of preparing anhydrous aripiprazole form II
JP5546717B2 (ja)	2003-12-16	2014-07-09	テバファーマシューティカルインダストリーズリミティド	アリピプラゾール結晶質形態を調製する方法
MXPA06008828A (es) *	2004-02-05	2007-04-25	Teva Pharma	Proceso para preparar aripiprazol.
EP1765782A1 (en)	2004-02-05	2007-03-28	Teva Pharmaceutical Industries Ltd	Method of making 7-(4-bromobutoxy)-3,4-dihydrocarbostyril
US7507823B2 (en)	2004-05-06	2009-03-24	Bristol-Myers Squibb Company	Process of making aripiprazole particles
EP1797039A1 (en) *	2004-09-13	2007-06-20	Matrix Laboratories Ltd	Process for the preparation of polymorphs, solvates of aripiprazole using aripiprazole acid salts
NZ554731A (en)	2004-10-08	2009-12-24	Suven Life Sciences Ltd	Novel Intermediates Useful For The Preparation Of Aripiprazole And Methods For The Preparation Of The Novel Intermediates And Aripiprazole
CN100338038C (zh) *	2004-10-14	2007-09-19	重庆医药工业研究院有限责任公司	阿立派唑的新晶型及其制备方法
CN101111481A (zh) *	2004-11-18	2008-01-23	斯索恩有限公司	制备结晶阿立哌唑的方法
CN101087760B (zh)	2004-11-18	2011-09-28	斯索恩有限公司	结晶的阿立哌唑溶剂化物
EP2093217B1 (en)	2005-01-27	2014-03-12	Sandoz AG	Process for preparing Form X of aripiprazole
EP1686117A1 (en) *	2005-01-27	2006-08-02	Sandoz AG	Polymorph and solvates of aripiprazole
ES2526415T3 (es)	2005-03-17	2015-01-12	Synthon B.V.	Comprimidos farmacéuticos de aripiprazol cristalino de tipo II
EP1858855B2 (en) †	2005-03-17	2021-03-03	Synthon B.V.	Process of making crystalline type ii aripiprazole
TWI320783B (en)	2005-04-14	2010-02-21	Otsuka Pharma Co Ltd	Heterocyclic compound
WO2007004061A1 (en) *	2005-04-15	2007-01-11	Medichem, S.A.	Syntheses and preparations of polymorphs of crystalline aripiprazole
CN100432053C (zh) *	2005-06-07	2008-11-12	上海医药工业研究院	阿立哌唑晶型及其制备方法
HUP0500683A3 (en) *	2005-07-14	2009-03-30	Egis Gyogyszergyar Nyilvanosan	New arylpiprazole salts for producing pharmaceutical composition
JP2008540644A (ja) *	2005-07-15	2008-11-20	テバファーマシューティカルインダストリーズリミティド	新規粒質化方法及びそれから生成される粒質物
US20070014853A1 (en) *	2005-07-15	2007-01-18	Ilan Zalit	Pharmaceutical dosage form containing novel pharmaceutical granulate
US20070014864A1 (en) *	2005-07-15	2007-01-18	Teva Pharmaceutical Industries, Ltd.	Novel pharmaceutical granulate
US20070014854A1 (en) *	2005-07-15	2007-01-18	Ilan Zalit	Novel granulation process
JP2009508859A (ja) *	2005-09-15	2009-03-05	エランファーマインターナショナルリミテッド	ナノ粒子アリピプラゾール製剤
EP1934183A1 (en)	2005-09-29	2008-06-25	Teva Pharmaceutical Industries Ltd	Methods of preparing anhydrous aripiprazole form ii
CZ299485B6 (cs) *	2005-10-11	2008-08-13	Zentiva, A. S.	Zpusob výroby aripiprazolu
BRPI0608185A2 (pt) *	2005-12-22	2009-11-17	Teva Pharma	processo para redução do tamanho de partìcula de aripiprazol
ES2318693T5 (es)	2006-01-05	2018-10-04	Teva Pharmaceutical Industries Ltd	Procedimiento de granulación en húmedo para la preparación de composiciones farmacéuticas de aripiprazol
US20070154545A1 (en) *	2006-01-05	2007-07-05	Julia Hrakovsky	Dry formulations of aripiprazole
TWI394753B (zh)	2006-03-17	2013-05-01	Otsuka Pharma Co Ltd	新穎替妥牟拉（ｔｅｔｏｍｉｌａｓｔ）晶體
US20060223820A1 (en) *	2006-03-21	2006-10-05	Chemagis Ltd.	Crystalline aripiprazole salts and processes for preparation and purification thereof
US7799790B2 (en)	2006-07-20	2010-09-21	Helm Ag	Amorphous aripiprazole and process for the preparation thereof
EP1880714A1 (en)	2006-07-20	2008-01-23	Helm AG	Amorphous Aripiprazole and Process for the Preparation thereof
TR200604349A2 (tr)	2006-08-15	2008-03-21	NOBEL İLAÇ SANAYii VE TiCARET A.Ş.	Aripiprazol içeren farmasötik bileşimler
GB0618879D0 (en)	2006-09-26	2006-11-01	Zysis Ltd	Pharmaceutical compositions
WO2008059518A2 (en) *	2006-09-28	2008-05-22	Cadila Healthcare Limited	Process for preparing crystalline aripiprazole
WO2008051541A2 (en) *	2006-10-24	2008-05-02	Cambrex Charles City, Inc.	Process for preparing anhydrous aripirazole type i
ECSP077628A (es)	2007-05-03	2008-12-30	Smithkline Beechman Corp	Nueva composición farmacéutica
NZ581560A (en) *	2007-06-25	2011-09-30	Otsuka Pharma Co Ltd	Microspheres having core/shell structure containing aripiprazole
NO2170279T3 (es)	2007-07-31	2018-05-26
ES2353444T3 (es)	2008-01-23	2011-03-02	Helm Ag	Aripiprazol amorfo y procedimiento para su preparación.
WO2010079506A2 (en)	2008-06-23	2010-07-15	Torrent Pharmaceuticals Ltd.	Pharmaceutical composition of aripiprazole
EP2233471A1 (en)	2009-02-06	2010-09-29	Adamed Sp. z o.o.	A salt of 7-{4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy}-3,4.dihydro-2(1h)-quinolinone with 5-sulfosalicylic acid and its preparation process
WO2010106551A2 (en) *	2009-03-09	2010-09-23	Neuland Laboratories Ltd.	A process for the manufacture of pure anhydrous aripiprazole form b
EP2238976B1 (en)	2009-04-03	2012-06-27	Hexal AG	Oral films comprising 7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro- 1H-quinolin-2-one base or salts or hydrates thereof
WO2011032882A1 (en)	2009-09-15	2011-03-24	Ratiopharm Gmbh	Orally disintegrating pharmaceutical dosage form containing aripiprazole
CN102372672B (zh) *	2010-08-24	2014-06-04	重庆圣华曦药业股份有限公司	低吸湿性阿立哌唑晶体iv、制备方法及其应用
CN101948426A (zh) *	2010-09-13	2011-01-19	浙江华海药业股份有限公司	一种制备阿立哌唑晶型b的新方法
JP2012121850A (ja) *	2010-12-09	2012-06-28	Otsuka Pharmaceut Co Ltd	アリピプラゾールの経口速溶性組成物
CN102060763B (zh) *	2010-12-27	2012-11-14	齐鲁制药有限公司	微粉型阿立哌唑晶型ⅰ或ⅱ的制备方法
AU2012231160B2 (en)	2011-03-18	2017-04-06	Alkermes Pharma Ireland Limited	Pharmaceutical compositions comprising sorbitan esters
WO2012131451A1 (en)	2011-03-30	2012-10-04	Jubilant Life Sciences Limited	Process for producing aripiprazole in anhydrous type i crystals
KR101340214B1 (ko)	2011-03-31	2013-12-10	주식회사 대웅제약	무수 아리피프라졸 ⅱ형 결정의 제조방법
JO3410B1 (ar)	2011-06-07	2019-10-20	Otsuka Pharma Co Ltd	تركيبة أريبيبرازول مجفف بالتبريد
JP6034377B2 (ja) *	2011-06-27	2016-11-30	シャンハイチョンシファーマシューティカルコーポレイション	アリピプラゾール医薬製剤及びその調製方法
CN102850268B (zh) *	2011-06-27	2015-07-15	上海中西制药有限公司	阿立哌唑ⅰ型微晶、阿立哌唑固体制剂及制备方法
TW201309651A (zh) *	2011-06-29	2013-03-01	Otsuka Pharma Co Ltd	阿立哌唑（ａｒｉｐｉｐｒａｚｏｌｅ）無水物Ｂ形結晶微粒子之製造方法
CN103172563B (zh) *	2011-12-26	2015-03-25	北京京卫燕康药物研究所有限公司	小粒径的晶型i阿立哌唑的工业化制备
CN102584858B (zh) *	2011-12-31	2014-11-12	广州医药工业研究院	乳酸左旋尤利沙星晶体及其制备方法和用途
AR090245A1 (es)	2012-03-06	2014-10-29	Otsuka Pharma Co Ltd	Preparacion solida oral de liberacion sostenida, metodo de preparacion
ES2764383T3 (es)	2012-03-19	2020-06-03	Alkermes Pharma Ireland Ltd	Composiciones farmacéuticas que comprenden ésteres de glicerol
US9999670B2 (en)	2012-03-19	2018-06-19	Alkermes Pharma Ireland Limited	Pharmaceutical compositions comprising benzyl alcohol
CA2867121C (en)	2012-03-19	2021-05-25	Alkermes Pharma Ireland Limited	Pharmaceutical compositions comprising fatty acid esters
TWI562991B (en) *	2012-04-23	2016-12-21	Otsuka Pharma Co Ltd	Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
JOP20200109A1 (ar)	2012-04-23	2017-06-16	Otsuka Pharma Co Ltd	مستحضر قابل للحقن
AR090775A1 (es) *	2012-04-23	2014-12-03	Otsuka Pharma Co Ltd	Preparado inyectable
EP2868319A4 (en)	2012-06-29	2016-02-24	Maruishi Pharma	ORAL PHARMACEUTICAL PREPARATION OF ARIPIPRAZOLE
KR101372840B1 (ko) *	2012-08-02	2014-03-12	주식회사 에스텍파마	무수 아리피프라졸 결정의 제조방법
JP6654042B2 (ja)	2012-09-19	2020-02-26	アルカームスファーマアイルランドリミテッド	貯蔵安定性が改善された医薬組成物
JP6007169B2 (ja) *	2012-11-30	2016-10-12	大原薬品工業株式会社	アリピプラゾール無水物を含有する固形製剤の製造方法
JP2014114243A (ja) *	2012-12-11	2014-06-26	Ohara Yakuhin Kogyo Kk	安定な固形製剤の製造方法
CN107129467A (zh) *	2013-03-26	2017-09-05	江苏恩华药业股份有限公司	阿立哌唑结晶b
AR096131A1 (es) *	2013-04-30	2015-12-09	Otsuka Pharma Co Ltd	Preparado oral sólido que comprende aripiprazol y un método para producir un preparado oral sólido que comprende aripiprazol
JP5931219B2 (ja) *	2013-04-30	2016-06-08	大塚製薬株式会社	アリピプラゾールを含む経口固形製剤、及びアリピプラゾールを含む経口固形製剤の製造方法
US10525057B2 (en)	2013-09-24	2020-01-07	Otsuka Pharmaceutical Co., Ltd.	Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
US20150093441A1 (en) *	2013-09-30	2015-04-02	Otsuka Pharmaceutical Co., Ltd	Oral solid preparation comprising aripiprazole and method for producing oral solid preparation comprising aripiprazole
EP3065700A1 (en)	2013-11-07	2016-09-14	Synthon B.V.	Orodispersible pharmaceutical compositions comprising aripiprazole
CN110368360A (zh)	2014-03-20	2019-10-25	奥克梅斯制药爱尔兰有限公司	具有增加的注射速度的阿立哌唑制剂
CN106575817B (zh) *	2014-08-18	2019-08-16	三星电子株式会社	电子装置的天线
US10064859B2 (en)	2014-08-25	2018-09-04	Alkermes Pharma Ireland Limited	Crystallization process of aripiprazole derivatives in extended release formulations for treatment of schizophrenia
JP6023770B2 (ja) *	2014-10-01	2016-11-09	株式会社パーマケム・アジア	アリピプラゾール無水物ｂ形結晶の製造方法
US10633336B2 (en)	2014-12-19	2020-04-28	The Broad Institute, Inc.	Dopamine D2 receptor ligands
WO2016138536A2 (en) *	2015-02-27	2016-09-01	Tactual Labs Co.	Alterable ground plane for touch surfaces
WO2016181406A1 (en) *	2015-05-08	2016-11-17	Davuluri Ramamohan Rao	Improved process for the preparation of aripiprazole with reduced particle size
JP6071083B2 (ja) *	2015-06-12	2017-02-01	大原薬品工業株式会社	安定性が改善された、アリピプラゾールを含有する散剤
JP2015172084A (ja) *	2015-07-06	2015-10-01	大塚製薬株式会社	アリピプラゾールの経口速溶性組成物
CN106474058B (zh)	2015-08-31	2020-01-07	南京诺瑞特医药科技有限公司	具有延长的保质期的阿立哌唑可注射悬浮液制剂
TWI665194B (zh) *	2016-02-19	2019-07-11	諾瑞特國際藥業股份有限公司	阿立哌唑的新晶型
US10913721B2 (en)	2016-02-19	2021-02-09	Nanjing Noratech Pharmaceuticals Co., Ltd	Crystalline form of aripiprazole
EP3426280A4 (en) *	2016-03-10	2019-10-23	The Regents of The University of Michigan	METHOD FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
JOP20190144A1 (ar)	2016-12-16	2019-06-16	Janssen Pharmaceutica Nv	إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
ES2922379T3 (es)	2016-12-16	2022-09-14	Janssen Pharmaceutica Nv	Compuestos de imidazo[4,5,D]pirrolo[2,3,B]piridina como inhibidores de Janus quinasas
JP6572257B2 (ja) *	2017-05-16	2019-09-04	大塚製薬株式会社	アリピプラゾールの経口速溶性組成物
AU2019230014B2 (en)	2018-03-05	2024-11-28	Alkermes Pharma Ireland Limited	Aripiprazole dosing strategy
TW202016110A (zh)	2018-06-15	2020-05-01	比利時商健生藥品公司	Ｊａｋ激酶家族之小分子抑制劑
EP3870292A4 (en)	2018-10-26	2022-11-09	The Research Foundation for The State University of New York	COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA
JP7211136B2 (ja) *	2019-02-14	2023-01-24	ニプロ株式会社	錠剤、および、その製造方法
CN110128337A (zh) *	2019-06-10	2019-08-16	岳阳新华达制药有限公司	一种阿立哌唑晶型b的制备方法
KR102128883B1 (ko)	2019-10-02	2020-07-01	(주)삼화바이오팜	고순도 아리피프라졸의 신규 결정형 및 이의 제조방법
BR112022018647A2 (pt)	2020-04-01	2022-11-08	Otsuka Pharma Co Ltd	Métodos para dose de iniciação de tratamentos com aripipazol
EP4043008A1 (en)	2021-02-15	2022-08-17	Warszawskie Zaklady Farmaceutyczne Polfa S.A.	Method for the preparation of a pharmaceutical composition comprising aripiprazole
EP4304590A1 (en)	2021-03-11	2024-01-17	Janssen Pharmaceutica NV	Lorpucitinib for use in the treatment of jak mediated disorders
WO2024225441A1 (en)	2023-04-26	2024-10-31	Otsuka Pharmaceutical Co., Ltd.	Dose initiation for schizophrenia or bipolar i disorder treatment with aripiprazole
CN117309825B (zh) *	2023-11-30	2024-04-09	四川蜀道建筑科技有限公司	一种透光检测亚甲蓝mb值的设备
CN118878462B (zh) *	2024-06-12	2025-05-09	青岛科技大学	一种药物微晶水中制备方法

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS62149664A (ja)	1978-03-30	1987-07-03	Otsuka Pharmaceut Co Ltd	カルボスチリル誘導体の製造法
JPS54130587A (en)	1978-03-30	1979-10-09	Otsuka Pharmaceut Co Ltd	Carbostyryl derivative
JPS5646812A (en)	1979-09-27	1981-04-28	Otsuka Pharmaceut Co Ltd	Central nervous system depressant
JPS55127371A (en)	1980-02-14	1980-10-02	Otsuka Pharmaceut Co Ltd	Carbostyril derivative
US4438119A (en)	1982-12-23	1984-03-20	Mead Johnson & Company	Method for alleviation of extrapyramidal motor disorders
DK588486A (da)	1985-12-09	1987-06-10	Otsuka Pharma Co Ltd	Anvendelse af en forbindelse til behandling af hypoxi
US4687772A (en)	1986-10-07	1987-08-18	Bristol-Myers Company	Method for improvement of short term memory
US4771053A (en)	1987-03-02	1988-09-13	Bristol-Myers Company	Method for alleviation of primary depressive disorders
US5162375A (en) *	1988-05-06	1992-11-10	Beecham Group P.L.C.	Treatment of neuronal degeneration with 5HT1A agonists
FR2640266B2 (fr) *	1988-07-12	1992-07-10	Synthelabo	Derives de (hydroxy-1 piperidinyl-2 alkyl) indolones-2, quinoleinones-2, benzo(b)azepinones-2 et benzimidazolones-2, leur preparation et leur application en therapeutique
EP0355583B1 (en) *	1988-08-10	1995-01-25	Otsuka Pharmaceutical Co., Ltd.	Cardiotonics
US5200410A (en) *	1988-09-20	1993-04-06	Troponwerke Gmbh & Co.	Medicaments for the treatment of cerebral apoplexy
DE3831888A1 (de)	1988-09-20	1990-03-29	Troponwerke Gmbh & Co Kg	Arzneimittel zur behandlung von apoplexia cerebri
FR2637591B1 (fr) *	1988-10-11	1992-10-23	Synthelabo	Derives de quinoleinone, leur preparation et leur application en therapeutique
JP2608788B2 (ja)	1988-10-31	1997-05-14	大塚製薬株式会社	精神分裂病治療剤
US5006528A (en) *	1988-10-31	1991-04-09	Otsuka Pharmaceutical Co., Ltd.	Carbostyril derivatives
US5073377A (en) *	1988-11-03	1991-12-17	Miles Inc.	Method of preparing oral dosage forms with a granulating composition
US5225402A (en) *	1989-02-10	1993-07-06	Otsuka Pharmaceutical Co., Ltd.	Carbostyril derivatives
GB9026389D0 (en) *	1990-12-05	1991-01-23	Merck Sharp & Dohme	Therapeutic agents
AU9164591A (en)	1990-12-14	1992-07-08	New York University	Functional interactions between glial s-100b and central nervous system serotonergic neurons
CA2067475C (en) *	1991-05-08	2000-10-10	Yasuo Oshiro	Carbostyril derivatives and their use
WO1992020655A1 (en)	1991-05-20	1992-11-26	The Upjohn Company	Carboxamido-(1,2n)-carbocyclic-2-aminotetralin derivatives
DE4135551A1 (de)	1991-08-31	1993-03-04	Schering Ag	Verwendung von antagonisten oder partiellen agonisten am 5-ht1a-rezeptor zur behandlung und praevention von kognitiven stoerungen
US5824680A (en) *	1991-08-31	1998-10-20	Bayer Aktiengesellschaft	Ipsapirone for the treatment of alzheimer's disease by improving memory
US5532240A (en) *	1991-12-26	1996-07-02	Yoshitomi Pharmaceutical Industries, Ltd.	Condensed thiophene compound and pharmaceutical use thereof
US5292766A (en)	1992-03-25	1994-03-08	Eli Lilly And Company	Method for improving primary memory and/or learning
WO1994009765A1 (en)	1992-10-23	1994-05-11	New York University	Functional interactions between glial s-100b and central nervous system serotonergic neurons
DK148292D0 (da)	1992-12-09	1992-12-09	Lundbeck & Co As H	Forbindelser
JP2506547B2 (ja)	1993-06-16	1996-06-12	ミナミ産業株式会社	豆腐のパック詰め装置
JP2959615B2 (ja)	1993-06-24	1999-10-06	吉富製薬株式会社	縮合型チオフェン化合物およびその医薬用途
JPH07247271A (ja) *	1994-01-21	1995-09-26	Otsuka Pharmaceut Co Ltd	３，４−ジヒドロカルボスチリル誘導体
US5663178A (en) *	1995-02-06	1997-09-02	Eli Lilly And Company	Tetrahydro-beta carbolines
US5504093A (en) *	1994-08-01	1996-04-02	Otsuka Pharmaceutical Co., Ltd.	Method for inhibiting nucleoside and nucleobase transport in mammalian cells, and method for inhibition of DNA virus replication
JP2987484B2 (ja)	1995-03-16	1999-12-06	大塚製薬株式会社	カルボスチリル誘導体の製造方法
JPH0940648A (ja)	1995-08-02	1997-02-10	Yamanouchi Pharmaceut Co Ltd	新規な８−（２−アミノアルコキシ）キノリン誘導体
DE69613081T2 (de)	1995-11-30	2002-03-07	Mitsui Chemicals, Inc.	Verstreckte Folie eines Milchsäurepolymers
JPH09291034A (ja)	1996-02-27	1997-11-11	Yoshitomi Pharmaceut Ind Ltd	縮合ピリジン化合物およびその医薬としての用途
US5688950A (en)	1996-04-23	1997-11-18	Neurogen Corporation	Tricyclic aminoalkylcarboxamides; novel dopamine D3 receptor subtype specific ligands
HU229057B1 (en)	1996-05-07	2013-07-29	Pfizer	Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2(1h)-indol-2-one (-ziprasidone), its preparation and its use as dopamine d2 antagonist
JP4012994B2 (ja)	1996-05-08	2007-11-28	大塚製薬株式会社	抗不安薬
EP1014977A1 (en)	1996-08-22	2000-07-05	Glaxo Group Limited	Diagnosis of migraine with aura, depression and anxiety from allelic variations in dopaminergic genes
AU4091697A (en)	1996-08-27	1998-03-19	American Home Products Corporation	4-aminoethoxy indoles as dopamin d2 agonists and as 5ht1a ligands
CA2317515A1 (en)	1998-02-03	1999-08-05	Frances Christy Nelson	Oxazole derivatives as serotonin-1a receptor agonists
JP2001089128A (ja) *	1998-04-10	2001-04-03	Asahi Glass Co Ltd	球状シリカ粒子の製造方法
JP2002511450A (ja)	1998-04-13	2002-04-16	アメリカン・ホーム・プロダクツ・コーポレイション	４−アミノ−（エチルアミノ）−オキソインドールドパミン自己受容体作動薬
WO1999055672A2 (en) *	1998-04-29	1999-11-04	American Home Products Corporation	Antipsychotic indolyl derivatives
JPH11335286A (ja)	1998-05-25	1999-12-07	Mitsui Chem Inc	ドーパミン拮抗薬の効果増強剤
US20030027817A1 (en) *	1998-05-29	2003-02-06	Tollefson Gary Dennis	Combination therapy for treatment of bipolar disorders
HN1999000146A (es)	1998-09-21	2000-11-11	Pfizer Prod Inc	Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas.
US6267989B1 (en)	1999-03-08	2001-07-31	Klan Pharma International Ltd.	Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions
PL356605A1 (en)	2000-01-19	2004-06-28	Akzo Nobel N.V.	Drug combination for the treatment of depression and related disorders comprising mirtazapine and gepirone
CA2311734C (en)	2000-04-12	2011-03-08	Bristol-Myers Squibb Company	Flash-melt oral dosage formulation
US20020076437A1 (en)	2000-04-12	2002-06-20	Sanjeev Kothari	Flashmelt oral dosage formulation
JP4197088B2 (ja)	2000-06-05	2008-12-17	電気化学工業株式会社	低密度かつ低ガス透過性六方晶窒化硼素焼結体及びその製造方法
NZ526801A (en)	2001-01-02	2005-07-29	Upjohn Co	Norepinephrine reuptake inhibitor i.e. reboxetine and neuroleptic to treat disorders of the central nervous system
AR032641A1 (es)	2001-01-29	2003-11-19	Otsuka Pharma Co Ltd	Agonista de subtipo de receptor 5-ht 1a.
US7053092B2 (en) *	2001-01-29	2006-05-30	Otsuka Pharmaceutical Co., Ltd.	5-HT1a receptor subtype agonist
ATE338557T1 (de)	2001-06-19	2006-09-15	Norbert Mueller	Verwendung von cox2 inhibitoren zur behandlung von schizophrenia und des ticks
AR033485A1 (es) *	2001-09-25	2003-12-26	Otsuka Pharma Co Ltd	Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
JP2003238393A (ja)	2002-02-15	2003-08-27	Otsuka Pharmaceut Co Ltd	施錠性が改善された錠剤及びその製造方法
AR042806A1 (es)	2002-12-27	2005-07-06	Otsuka Pharma Co Ltd	Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
EP2601953A1 (en)	2003-05-23	2013-06-12	Otsuka Pharmaceutical Co., Ltd.	Carbostyril derivatives and mood stabilizers for treating mood disorders
PL1675573T4 (pl)	2003-10-23	2016-04-29	Otsuka Pharma Co Ltd	Sterylny preparat do wstrzykiwań arypiprazolu o kontrolowanym uwalnianiu i sposób
CA2658146A1 (en)	2006-07-12	2008-01-17	Nerviano Medical Sciences S.R.L.	Crystalline nemorubicin hydrochloride
EP2223702B1 (en)	2007-12-03	2019-05-08	Tomita Pharmaceutical Co., Ltd.	Core particle for pharmaceutical preparation
GB2456183A (en)	2008-01-04	2009-07-08	Gw Pharma Ltd	Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament

2002
- 2002-09-18 AR ARP020103511A patent/AR033485A1/es not_active Application Discontinuation
- 2002-09-20 PE PE2008001435A patent/PE20090124A1/es not_active Application Discontinuation
- 2002-09-25 ES ES08000359T patent/ES2343220T3/es not_active Expired - Lifetime
- 2002-09-25 PT PT08000357T patent/PT1927355E/pt unknown
- 2002-09-25 CN CN2009101474911A patent/CN101574348B/zh not_active Expired - Fee Related
- 2002-09-25 WO PCT/JP2002/009858 patent/WO2003026659A1/en not_active Ceased
- 2002-09-25 ES ES02782507T patent/ES2261750T3/es not_active Expired - Lifetime
- 2002-09-25 HU HU0600141A patent/HUP0600141A3/hu unknown
- 2002-09-25 DK DK08000359.3T patent/DK1927356T3/da active
- 2002-09-25 PT PT04002427T patent/PT1419776E/pt unknown
- 2002-09-25 CN CN201610811281.8A patent/CN106420640A/zh active Pending
- 2002-09-25 JP JP2002279085A patent/JP3760264B2/ja not_active Expired - Lifetime
- 2002-09-25 CN CN201710019464.0A patent/CN106692151A/zh active Pending
- 2002-09-25 DE DE60235995T patent/DE60235995D1/de not_active Expired - Lifetime
- 2002-09-25 DK DK04002427.5T patent/DK1419776T4/en active
- 2002-09-25 EP EP08000360A patent/EP1927357B1/en not_active Expired - Lifetime
- 2002-09-25 CN CN200610006215XA patent/CN1817882B/zh not_active Expired - Lifetime
- 2002-09-25 AU AU2002334413A patent/AU2002334413C1/en not_active Expired
- 2002-09-25 CN CN2009101474907A patent/CN101574347B/zh not_active Expired - Fee Related
- 2002-09-25 DE DE60236231T patent/DE60236231D1/de not_active Expired - Lifetime
- 2002-09-25 CA CA2688915A patent/CA2688915C/en not_active Expired - Lifetime
- 2002-09-25 CA CA2689052A patent/CA2689052C/en not_active Expired - Lifetime
- 2002-09-25 CN CN201610811822.7A patent/CN106420627A/zh active Pending
- 2002-09-25 MX MXPA03000440A patent/MXPA03000440A/es active IP Right Grant
- 2002-09-25 PT PT08000360T patent/PT1927357E/pt unknown
- 2002-09-25 AT AT08000359T patent/ATE465737T1/de active
- 2002-09-25 AT AT02782507T patent/ATE322269T1/de active
- 2002-09-25 CN CN200910266341A patent/CN101792415A/zh active Pending
- 2002-09-25 CN CN2009101474930A patent/CN101579344B/zh not_active Expired - Fee Related
- 2002-09-25 IL IL15383802A patent/IL153838A0/xx unknown
- 2002-09-25 AT AT08000360T patent/ATE467416T1/de active
- 2002-09-25 US US10/333,244 patent/US20040058935A1/en not_active Abandoned
- 2002-09-25 DE DE60236229T patent/DE60236229D1/de not_active Expired - Lifetime
- 2002-09-25 CA CA2426921A patent/CA2426921C/en not_active Expired - Lifetime
- 2002-09-25 DK DK08000360.1T patent/DK1927357T3/da active
- 2002-09-25 EP EP08000359A patent/EP1927356B1/en not_active Expired - Lifetime
- 2002-09-25 SI SI200230337T patent/SI1330249T1/sl unknown
- 2002-09-25 DK DK02782507T patent/DK1330249T3/da active
- 2002-09-25 PL PL360900A patent/PL225415B1/pl not_active IP Right Cessation
- 2002-09-25 CA CA2688934A patent/CA2688934C/en not_active Expired - Lifetime
- 2002-09-25 CA CA002688860A patent/CA2688860A1/en not_active Abandoned
- 2002-09-25 PT PT02782507T patent/PT1330249E/pt unknown
- 2002-09-25 CN CNA2008101254118A patent/CN101434575A/zh active Pending
- 2002-09-25 DK DK08000357.7T patent/DK1927355T3/da active
- 2002-09-25 AT AT08000357T patent/ATE465736T1/de active
- 2002-09-25 CN CN2008101254071A patent/CN101423492B/zh not_active Expired - Fee Related
- 2002-09-25 EP EP08000358.5A patent/EP1925308B1/en not_active Revoked
- 2002-09-25 EP EP08000357A patent/EP1927355B1/en not_active Expired - Lifetime
- 2002-09-25 ES ES08000357T patent/ES2343219T3/es not_active Expired - Lifetime
- 2002-09-25 DE DE60210409T patent/DE60210409T2/de not_active Expired - Lifetime
- 2002-09-25 UA UAA200612812 patent/UA84764C2/uk unknown
- 2002-09-25 CN CN2009101474926A patent/CN101579343B/zh not_active Expired - Fee Related
- 2002-09-25 CA CA2689051A patent/CA2689051C/en not_active Expired - Lifetime
- 2002-09-25 CN CNA2005100785991A patent/CN1699346A/zh active Pending
- 2002-09-25 EP EP02782507A patent/EP1330249B1/en not_active Revoked
- 2002-09-25 CN CN2008101254103A patent/CN101434574B/zh not_active Expired - Fee Related
- 2002-09-25 ES ES08000360T patent/ES2343602T3/es not_active Expired - Lifetime
- 2002-09-25 DE DE60236383T patent/DE60236383D1/de not_active Expired - Lifetime
- 2002-09-25 ES ES04002427.5T patent/ES2343179T5/es not_active Expired - Lifetime
- 2002-09-25 PT PT08000359T patent/PT1927356E/pt unknown
- 2002-09-25 CN CN2008101254090A patent/CN101434573B/zh not_active Expired - Fee Related
- 2002-09-25 AT AT04002427T patent/ATE464050T1/de active
- 2002-09-25 SI SI200230904T patent/SI1927356T1/sl unknown
- 2002-09-25 BR BR0205391-8A patent/BR0205391A/pt not_active Application Discontinuation
- 2002-09-25 SI SI200230903T patent/SI1419776T2/sl unknown
- 2002-09-25 SI SI200230905T patent/SI1927355T1/sl unknown
- 2002-09-25 CN CNA2008101254086A patent/CN101423493A/zh active Pending
- 2002-09-25 EP EP04002427.5A patent/EP1419776B2/en not_active Expired - Lifetime
- 2002-09-25 CN CN02801754A patent/CN1463191A/zh active Pending
2003
- 2003-01-07 IL IL153838A patent/IL153838A/en not_active IP Right Cessation
- 2003-01-17 NO NO20030247A patent/NO328134B1/no not_active IP Right Cessation
2004
- 2004-05-26 JP JP2004156130A patent/JP3750023B2/ja not_active Expired - Lifetime
2005
- 2005-11-25 JP JP2005341187A patent/JP4614870B2/ja not_active Expired - Lifetime
2006
- 2006-09-08 AR ARP060103919A patent/AR056503A2/es not_active Application Discontinuation
2007
- 2007-04-26 US US11/790,604 patent/US8399469B2/en not_active Expired - Lifetime
- 2007-04-26 US US11/790,605 patent/US8017615B2/en not_active Expired - Lifetime
- 2007-04-26 US US11/790,603 patent/US20070213343A1/en not_active Abandoned
- 2007-04-26 US US11/790,606 patent/US7910589B2/en not_active Expired - Lifetime
- 2007-04-30 US US11/797,030 patent/US20070203152A1/en not_active Abandoned
- 2007-04-30 US US11/797,024 patent/US20070203151A1/en not_active Abandoned
- 2007-04-30 US US11/797,019 patent/US20070203150A1/en not_active Abandoned
- 2007-12-27 IL IL188455A patent/IL188455A0/en not_active IP Right Cessation
2008
- 2008-04-02 NO NO20081632A patent/NO336262B1/no not_active IP Right Cessation
- 2008-04-02 NO NO20081627A patent/NO336265B1/no not_active IP Right Cessation
- 2008-04-02 NO NO20081631A patent/NO336263B1/no not_active IP Right Cessation
- 2008-04-02 NO NO20081633A patent/NO20081633L/no not_active Application Discontinuation
- 2008-04-02 NO NO20081626A patent/NO336264B1/no not_active IP Right Cessation
2009
- 2009-04-28 NO NO20091689A patent/NO336679B1/no not_active IP Right Cessation
2011
- 2011-06-23 US US13/067,750 patent/US8642760B2/en not_active Expired - Lifetime
- 2011-06-29 US US13/067,838 patent/US8901303B2/en not_active Expired - Fee Related
2012
- 2012-01-13 US US13/350,117 patent/US8580796B2/en not_active Expired - Fee Related
- 2012-05-21 US US13/476,758 patent/US8901130B2/en not_active Expired - Fee Related
- 2012-05-21 US US13/476,773 patent/US8703773B2/en not_active Expired - Lifetime
2013
- 2013-01-25 US US13/749,753 patent/US8993761B2/en not_active Expired - Fee Related
- 2013-10-09 US US14/049,777 patent/US9359302B2/en not_active Expired - Fee Related
2015
- 2015-02-18 US US14/624,595 patent/US10150735B2/en not_active Expired - Fee Related
2016
- 2016-05-09 US US15/149,522 patent/US20160251315A1/en not_active Abandoned
- 2016-11-03 CY CY20161101119T patent/CY1118195T1/el unknown
2018
- 2018-10-24 US US16/169,255 patent/US20190225584A1/en not_active Abandoned
2019
- 2019-12-18 US US16/718,281 patent/US20200123110A1/en not_active Abandoned
2021
- 2021-01-28 US US17/160,716 patent/US20210395204A1/en not_active Abandoned

Also Published As

Publication number	Publication date
NO20030247D0 (no)	2003-01-17
DK1419776T3 (da)	2010-07-05
US7910589B2 (en)	2011-03-22
DE60236383D1 (de)	2010-06-24
CA2426921A1 (en)	2003-04-03
CN101792415A (zh)	2010-08-04
NO20081632L (no)	2003-01-17
US20140030523A1 (en)	2014-01-30
US20190225584A1 (en)	2019-07-25
CN101423492B (zh)	2013-08-28
NO20081626L (no)	2003-01-17
WO2003026659A1 (en)	2003-04-03
CA2688915C (en)	2011-02-01
HUP0600141A3 (en)	2008-03-28
PL360900A1 (en)	2004-09-20
PE20090124A1 (es)	2009-03-07
HUP0600141A2 (hu)	2006-05-29
US8399469B2 (en)	2013-03-19
AR056503A2 (es)	2007-10-10
JP3760264B2 (ja)	2006-03-29
US20210395204A1 (en)	2021-12-23
CN101434575A (zh)	2009-05-20
CN101579343A (zh)	2009-11-18
DK1330249T3 (da)	2006-08-07
CA2688934A1 (en)	2003-04-03
DE60210409T2 (de)	2006-11-16
UA84764C2 (en)	2008-11-25
EP1419776A2 (en)	2004-05-19
CN106692151A (zh)	2017-05-24
PT1927355E (pt)	2010-06-11
ES2343179T3 (es)	2010-07-26
US20140309236A1 (en)	2014-10-16
NO20030247L (no)	2003-01-17
CN1817882A (zh)	2006-08-16
US8580796B2 (en)	2013-11-12
DK1927357T3 (da)	2010-08-16
NO336264B1 (no)	2015-07-06
ES2343220T3 (es)	2010-07-26
EP1925308A1 (en)	2008-05-28
NO336263B1 (no)	2015-07-06
CY1118195T1 (el)	2017-06-28
CN106420627A (zh)	2017-02-22
ATE464050T1 (de)	2010-04-15
DK1927355T3 (da)	2010-07-19
DK1419776T4 (en)	2017-09-04
CN106420640A (zh)	2017-02-22
ATE322269T1 (de)	2006-04-15
US20040058935A1 (en)	2004-03-25
CN101574347B (zh)	2012-02-29
EP1925308B1 (en)	2016-08-31
US20120316180A1 (en)	2012-12-13
EP1419776A8 (en)	2004-09-01
EP1419776A3 (en)	2004-06-16
US8901130B2 (en)	2014-12-02
CN101434574A (zh)	2009-05-20
CN101574348A (zh)	2009-11-11
US20120316179A1 (en)	2012-12-13
ES2343602T3 (es)	2010-08-04
EP1927357B1 (en)	2010-05-12
JP2004256555A (ja)	2004-09-16
SI1419776T1 (sl)	2010-07-30
US20150225347A1 (en)	2015-08-13
NO336262B1 (no)	2015-07-06
AR033485A1 (es)	2003-12-26
CN1699346A (zh)	2005-11-23
US20070203151A1 (en)	2007-08-30
SI1419776T2 (sl)	2017-12-29
CA2688915A1 (en)	2003-04-03
ATE467416T1 (de)	2010-05-15
ES2343219T3 (es)	2010-07-26
BR0205391A (pt)	2003-07-29
US20160251315A1 (en)	2016-09-01
IL153838A (en)	2008-04-13
ES2261750T3 (es)	2006-11-16
ES2343179T5 (es)	2017-10-19
US8901303B2 (en)	2014-12-02
EP1330249B1 (en)	2006-04-05
JP3750023B2 (ja)	2006-03-01
CA2689052C (en)	2011-02-15
PT1330249E (pt)	2006-06-30
CA2426921C (en)	2011-03-15
SI1927355T1 (sl)	2010-07-30
US8993761B2 (en)	2015-03-31
US20120315302A1 (en)	2012-12-13
AU2002334413C1 (en)	2021-08-12
CN1463191A (zh)	2003-12-24
EP1927356A1 (en)	2008-06-04
IL153838A0 (en)	2003-07-31
PT1927357E (pt)	2010-06-08
SI1330249T1 (sl)	2006-10-31
US20120016123A1 (en)	2012-01-19
ATE465736T1 (de)	2010-05-15
NO336265B1 (no)	2015-07-06
CN101423493A (zh)	2009-05-06
SI1927356T1 (sl)	2010-07-30
CA2689052A1 (en)	2003-04-03
EP1419776B2 (en)	2017-07-19
AU2002334413B2 (en)	2004-11-04
CN101574347A (zh)	2009-11-11
EP1330249A1 (en)	2003-07-30
EP1419776A9 (en)	2004-09-08
NO20081631L (no)	2003-01-17
US9359302B2 (en)	2016-06-07
CN101579344A (zh)	2009-11-18
CN101574348B (zh)	2012-02-22
US20070213344A1 (en)	2007-09-13
NO336679B1 (no)	2015-10-19
PT1927356E (pt)	2010-05-24
NO20081627L (no)	2003-01-17
PT1419776E (pt)	2010-04-28
CN101434573A (zh)	2009-05-20
EP1419776B1 (en)	2010-04-14
CA2689051C (en)	2011-03-08
CN101434573B (zh)	2011-12-07
DE60235995D1 (de)	2010-05-27
CN1817882B (zh)	2011-09-07
US20200123110A1 (en)	2020-04-23
CN101579344B (zh)	2012-05-30
EP1927355A1 (en)	2008-06-04
ATE465737T1 (de)	2010-05-15
US20070212421A1 (en)	2007-09-13
JP2003212852A (ja)	2003-07-30
JP4614870B2 (ja)	2011-01-19
EP1927356B1 (en)	2010-04-28
CA2688934C (en)	2011-05-17
IL188455A0 (en)	2008-03-20
US20070203150A1 (en)	2007-08-30
NO20091689L (no)	2003-01-17
NO328134B1 (no)	2009-12-14
EP1927357A3 (en)	2008-06-11
CA2688860A1 (en)	2003-04-03
CA2689051A1 (en)	2003-04-03
EP1927355B1 (en)	2010-04-28
DK1927356T3 (da)	2010-07-26
DE60210409D1 (de)	2006-05-18
CN101423492A (zh)	2009-05-06
US8017615B2 (en)	2011-09-13
DE60236229D1 (de)	2010-06-10
CN101579343B (zh)	2012-04-18
US8703773B2 (en)	2014-04-22
US20120000998A1 (en)	2012-01-05
DE60236231D1 (de)	2010-06-10
PL225415B1 (pl)	2017-04-28
JP2006070045A (ja)	2006-03-16
NO20081633L (no)	2003-01-17
US20070202181A1 (en)	2007-08-30
US8642760B2 (en)	2014-02-04
US10150735B2 (en)	2018-12-11
EP1927357A2 (en)	2008-06-04
CN101434574B (zh)	2011-12-14
US20070203152A1 (en)	2007-08-30
US20070213343A1 (en)	2007-09-13
AU2002334413C9 (en)	2015-04-09

Publication	Publication Date	Title
PL360900A1 (en)	2004-09-20	Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
NZ504017A (en)	2001-09-28	Preparation of gatifloxacin and disodium edetate
IL149681A0 (en)	2002-11-10	Polymorphic form of atorvstatin calcium
WO2003000695A8 (en)	2004-03-11	Pyrrolopyrimidines as protein kinase inhibitors
EA200301165A1 (ru)	2004-06-24	Лекарственное средство на основе оксикодона
HUP0301842A3 (en)	2010-03-29	Lactam compound, pharmaceutical composition containing it and use of it for producing pharmaceutical composition
EP1246608A4 (en)	2005-05-18	PHARMACEUTICAL PREPARATIONS FOR THE ADMINISTRATION OF ACTIVE SUBSTANCES WITH LOW WATER SOLUBILITY
HUP0000979A1 (hu)	2000-10-28	FK-506 jelű vegyületet és származékait tartalmazó gyógyászati készítmények
ATE369857T1 (de)	2007-09-15	Methode zur stabilisierung von benzimidazol- verbindungen
SI1441769T1 (sl)	2005-12-31	Farmacevtske formulacije, ki vsebujejo nizke koncentracije peroksida, za zdravljenje ali preprecevanje vaginalnih infekcij
PH12014500782A1 (en)	2018-09-10	Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
MXPA03004303A (es)	2003-08-19	DERIVADOS SUSTITUIDOS DE ACIDO AMINO-FURAN-2-IL-ACETICO Y ACIDO AMINO-TIEN-2-IL-ACETICO Y SU USO PARA EL TRATAMIENTO DE MIGRAnA Y DOLOR.
HUP0300402A3 (en)	2005-07-28	Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain and pharmaceutical compositions containing them
UA80802C2 (en)	2007-11-12	Low hygroscopic aripiprazole drug substance and process for the preparation thereof
DE69930621D1 (de)	2006-05-18	Medizinische zusammensetzungen zur unmittelbaren freisetzung bei oraler anwendung
BR0211223A (pt)	2004-08-10	Derivados de 4-aminociclohexanol substituìdos
HUP0400925A3 (en)	2004-10-28	Azolycarbynol derivatives of aryl (or heteroaryl) for producing pharmaceutical compositions for the treatment of respiratory diseases
GEP20053457B (en)	2005-02-25	Low Hygroscopic Aripiprazole Drug Substance and Processes for Preparation Thereof
NO307753B1 (no)	2000-05-22	Krystaller av antimikrobielle forbindelser i anhydratform og anvendelse og farmasøytiske preparater derav
AU7402201A (en)	2001-12-03	Use of substituted 1-amino-5-phenylpentane-3-ol and/or 1-amino-6-phenylhexane-3-ol compounds as medicaments
EP1541144A4 (en)	2007-08-08	INDOMETHACINE PREPARATION FOR TOPICAL APPLICATION
MY138319A (en)	2009-05-29	1,5-benzodiazepine derivatives
BG103923A (en)	2000-06-30	Sulphate salt of hiv protease inhibitor with improved peroral absorption and biopresence
PL357568A1 (en)	2004-07-26	Novel pyrazine derivatives or salts thereof, pharmaceutical compositions containing the derivatives or the salts and intermediates for the preparation of both

Legal Events

Date	Code	Title	Description
2006-12-20	FG	Grant or registration
2014-05-12	GD	Licence granted